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7RESEARCH Open AccessElevated plasma heparin-binding protein is
associated with early death after
resuscitation from cardiac arrest
Giuseppe Ristagno1, Serge Masson1, Marjaana Tiainen2, Stepani Bendel3, Roberto Bernasconi1, Tero Varpula4,
Valentina Milani1, Jukka Vaahersalo4, Michela Magnoli1, Eberhard Spanuth5, Simona Barlera1, Roberto Latini1,
Sanna Hoppu6, Ville Pettilä4,7, Markus B. Skrifvars4,8* and FINNRESUSCI Study GroupAbstract
Background: An intense systemic inflammatory response is observed following reperfusion after cardiac arrest.
Heparin-binding protein (HBP) is a granule protein released by neutrophils that intervenes in endothelial permeability
regulation. In the present study, we investigated plasma levels of HBP in a large population of patients resuscitated
from out-of-hospital cardiac arrest. We hypothesized that high circulating levels of HBP are associated with severity of
post-cardiac arrest syndrome and poor outcome.
Methods: Plasma was obtained from 278 patients enrolled in a prospective multicenter observational study in 21
intensive care units (ICU) in Finland. HBP was assayed at ICU admission and 48 h later. Multiple organ dysfunction
syndrome (MODS) was defined as the 24 h Sequential Organ Failure Assessment (SOFA) score ≥ 12. ICU death
and 12-month Cerebral Performance Category (CPC) were evaluated. Multiple linear and logistic regression
tests and receiver operating characteristic curves with area under the curve (AUC) were performed.
Results: Eighty-two percent of patients (229 of 278) survived to ICU discharge and 48 % (133 of 276) to
1 year with a favorable neurological outcome (CPC 1 or 2). At ICU admission, median plasma levels of HBP
were markedly elevated, 15.4 [9.6–31.3] ng/mL, and persisted high 48 h later, 14.8 [9.8–31.1] ng/mL. Admission
levels of HBP were higher in patients who had higher 24 h SOFA and cardiovascular SOFA score (p < 0.0001)
and in those who developed MODS compared to those who did not (29.3 [13.7–60.1] ng/mL vs. 13.6 [9.1–26.2] ng/mL,
p < 0.0001; AUC = 0.70 ± 0.04, p = 0.0001). Admission levels of HBP were also higher in patients who died in ICU
(31.0 [17.7–78.2] ng/mL) compared to those who survived (13.5 [9.1–25.5] ng/mL, p < 0.0001) and in those with
an unfavorable 12-month neurological outcome compared to those with a favorable one (18.9 [11.3–44.3] ng/mL
vs. 12.8 [8.6–30.4] ng/mL, p < 0.0001). Admission levels of HBP predicted early ICU death with an AUC of 0.74 ± 0.
04 (p < 0.0001) and were independently associated with ICU death (OR [95 %CI] 1.607 [1.076–2.399], p = 0.020),
but not with unfavorable 12-month neurological outcome (OR [95 %CI] 1.154 [0.834–1.596], p = 0.387).
Conclusions: Elevated plasma levels of HBP at ICU admission were independently associated with early death
in ICU.
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Despite initially successful resuscitation, mortality after
cardiac arrest remains high, with more than half of
patients not surviving to hospital discharge due to “post-
cardiac arrest syndrome” [1, 2]. Beside myocardial dys-
function and evolving brain injury, a prominent patho-
physiological process characterizing such a syndrome is
the systemic inflammation subsequent to whole-body
ischemia/reperfusion [2–6]. Accordingly, the systemic
inflammatory response observed after cardiopulmonary
resuscitation (CPR) provides evident similarities to sepsis
and septic shock, with progression toward circulatory
failure and multiple organ dysfunction syndrome (MODS)
[4, 5]. Indeed, severe organ dysfunction in two or more
organ systems is very common in post-cardiac arrest
patients and is associated with early mortality [7].
Heparin-binding protein (HBP), also called azurocidin
or cationic antimicrobial protein of 37 kDa, is a multi-
functional protein contained within the secretory and
azurophilic granules of polymorphonuclear leukocytes,
and is rapidly released upon adhesion of leukocytes to
endothelial cells. Once released, HBP acts as chemo-
attractant and activator of monocytes and macrophages,
and increases vascular permeability with consequent
edema and hypoperfusion [8, 9].
The systemic inflammatory response following resusci-
tation from cardiac arrest includes leukocyte activation,
endothelial injury, and vascular response with vascular
leakage; thus, elevation in plasma levels of HBP is ex-
pected and might represent a potential prognostic marker
[2–4]. Indeed, in a small cohort of cardiac arrest patients,
early elevation of HBP after resuscitation predicted organ
failure and poor long-term neurological outcome [10]. In
the present observational study, we examined HBP plasma
levels in a large population of patients resuscitated from
out-of-hospital cardiac arrest. Since HBP has been shown
to predict circulatory failure and increase risk of death in
the critically ill patient [9–12], we hypothesized that high
circulating levels of HBP in patients resuscitated from
cardiac arrest would be associated with the severity of
organ dysfunction and early death.
Methods
Study design, setting, and selection of participants
The study was an observational cohort study, in which
plasma levels of HBP were assessed in adult patients
resuscitated from out-of-hospital cardiac arrest. Pa-
tients included in the present study were part of the
FINNRESUSCI study, a nationwide prospective obser-
vational cohort study conducted in 21 hospitals in
Finland between March 1, 2010 and February 28, 2011
and aiming to evaluate post-resuscitation care and out-
come of out-of-hospital cardiac arrest [13]. The study was
approved by the ethics committee of the Helsinki andUusimaa Hospital district (FINNRESUSCI TUTKIMUS
§10, 20.1.201) in addition to local ethics approvals in
six of the World Medical Association Declaration of
Helsinki. Informed consent from the patient’s next of
kin was obtained for data collection and blood sam-
pling. All cardiac arrest patients in whom blood sam-
ples were obtained at intensive care unit (ICU)
admission were included in the study. Information on
the 12-month neurological outcome was available for
276 patients. Thus, these 276 patients were included in
the long-term outcome analysis.
Data collection, processing, and outcomes
The participating hospitals were a part of the Finnish
Intensive Care Consortium (FICC) and used the same
electronic data management system and data validation
software (Web Validator, Tieto, Helsinki, Finland). Data
on study patients were prospectively collected using an
internet-based case report form. Pre-hospital data were
collected by the paramedics in accordance with the
Utstein Guidelines and included: whether the arrest was
witnessed or not; the administration of bystander-initiated
life support; the time from call to the dispatch center and
return of spontaneous circulation (ROSC); and the use of
adrenaline. In-hospital care data were collected electronic-
ally and comprised the use of vasopressors and induced
hypothermia, the Sequential Organ Failure Assessment
(SOFA) score, the Acute Physiology and Chronic Health
Evaluation (APACHE) II score, and ICU mortality. The
condition of MODS was defined as a SOFA score ≥ 12
[14, 15]. More specifically, the SOFA score was reported
as worst value during the first 24 hours (h) of ICU care. A
specialist in neurology blinded to the management in the
ICU contacted patients discharged from the hospital by
phone 1 year after cardiac arrest and determined neuro-
logical outcome according to the Pittsburgh Cerebral Per-
formance Categories (CPC). We defined 12-month good
outcome as CPC 1–2, and 12-month poor outcome as
CPC 3–5.
Methods of measurement
Plasma levels of HBP at ICU admission and 48 hours
later were measured blinded to case identity and clinical
data. Blood samples were collected into ethylenedi-
aminetetraacetic (EDTA) acid tubes and were kept at
room temperature for 30–60 min before being centri-
fuged at 2200 g for 10 min. Plasma samples were then
frozen at -20 °C in each participating hospital, prior to
being transferred in frozen form to Kuopio University
Hospital, where they were stored at -70 °C. Upon ana-
lysis, samples were thawed and divided into aliquots.
HBP levels were assayed in a single batch using an enzyme
immunoassay from Axis-Shield Diagnostics (Dundee,
Scotland), according to manufacturer’s recommendations.
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assay coefficients of variation were measured in 11
replicates and were 11 % at 21 ng/mL and 7 % at
81 ng/mL.Statistical analysis
Categorical variables are presented as proportions and
continuous variables as median with interquartile range
(IQR). Baseline characteristics by outcomes occurrence
were investigated with the chi-square test for categorical
variables; continuous variables were compared by ana-
lysis of variance or by the nonparametric Kruskal-Wallis
test for continuous non-normally distributed data. Mul-
tivariable linear regression was performed on natural
logarithm-transformed HBP values to identify the inde-
pendent factors at resuscitation influencing inflamma-
tory biomarkers levels at ICU admission and 48 h later.
Results of linear regression are reported in terms of
percent change (exponential of beta coefficient) and p
values. Multivariable logistic regression was used to
identify factors that were predictors of MODS, ICU
mortality, and 12-month poor neurological outcome.
Age, sex, and all other variables associated with the
outcome in the univariate analysis (p < 0.05) were in-
cluded in the multivariable model. Odds ratios (OR)
with the corresponding 95 % confidence interval (CI)
were calculated and p values were considered statistically
significant if they were less than 0.05. For each multivar-
iable logistic model, collinearity and calibration were
assessed respectively by value of variance inflaction factor
(VIF) and Hosmer-Lemeshow test. The discrimination
ability of inflammatory biomarkers was evaluated by re-
ceiver operating characteristic curve (ROC) analyses. All
statistical analyses were performed with SAS software,
version 9.2 (SAS Institute, Inc., Cary, NC, USA).Table 1 Baseline characteristics and clinical factors at resuscitation in
patients with good and poor outcome at 12 months
Whole population
(n = 278)
ICU surv
Yes (n =
Age, mean (SD) 63 ± 13 63 ± 12
Sex (male), n (%) 229 (82) 189 (83)
Shockable rhythm, n (%) 180 (65) 163 (71)*
Witnessed cardiac arrest, n (%) 254 (91) 212 (93)
Bystander-initiated BLS, n (%) 158 (57) 133 (58)
Adrenaline used, n (%) 186 (67) 141 (62)*
Time to ROSC in min, mean (SD) 21 ± 11 20 ± 11*
Therapeutic hypothermia, n (%) 202 (73) 173 (76)*
Chi-square test for categorical variables; analysis of variance (ANOVA) for continuou
ICU intensive care unit, SD standard deviation, BLS basic life support, ROSC return o
°Data on 12-month survival/outcome were missing for two patients
*p < 0.05 and **p < 0.01 vs. ICU death; §p < 0.01 vs. poor outcome at 12 monthsResults
The FINNIRESUSCI study included 548 patients [13],
whose clinical characteristics are reported in Additional
file 1. Among these, informed consent for blood sam-
pling was obtained for 245 patients at the time of ICU
admission and for an additional 33 patients prior to
subsequent sampling 48 h later, giving a total study sam-
ple of 278 patients. For these 278 patients, data were
available from 245 patients at ICU admission and from
222 patients 48 h later, due to either death or patient
transfer. Eighty-two percent of patients (229 of 278)
survived to ICU discharge and 48 % (133 of 276) had
favorable neurological outcome (CPC 1 or 2) at 12 months
(Table 1). Baseline characteristics and factors influencing
ICU survival and 12-month outcome are shown in Table 1.
Pre-hospital factors univariately associated with ICU sur-
vival were a shockable rhythm, no use of adrenaline, a
shorter time to ROSC, and the induction of hypothermia,
while those associated with long-term survival and good
neurological outcome included also a younger age and a
witnessed cardiac arrest (Table 1).
Normal values for plasma HBP in the general popula-
tion are approximately 6 ng/mL [16, 17]. In our patients,
median plasma levels of HBP were more than twofold,
15.4 [9.6–31.3] ng/mL, at ICU admission and persisted
high 48 h later 14.8 [9.8–31.1] ng/mL. Levels of HBP
were significantly higher in patients with an initial non-
shockable rhythm compared to those with a shockable
rhythm, and in the instance of longer time to return of
spontaneous circulation (ROSC) (Table 2). By linear re-
gression models, the common independent determinants
of levels of HBP were: the presence of a non-shockable
rhythm (64 % increase from shockable to non-shockable,
p < 0.0001 at ICU admission, and 54 % increase at 48 h,
p = 0.013) and a longer time to ROSC (1.6 % increase for
each minute, p = 0.009 at ICU admission).all patients and between ICU survivors and non-survivors and
ival 12-month neurological outcome°
229) No (n = 49) Good (n = 133) Poor (n = 143)
64 ± 14 60 ± 12§ 65 ± 13
40 (82) 109 (82) 119 (83)
* 17 (35) 108 (81)§ 71 (50)
42 (86) 128 (96)§ 124 (87)
25 (51) 82 (62) 76 (53)
* 45 (92) 67 (50)§ 118 (83)
* 25 ± 10 18 ± 10§ 24 ± 11
29 (59) 104 (78) 97 (68)
s variables
f spontaneous circulation
Table 2 Heparin-binding protein (HBP) levels by age, cardiac arrest
(CA) presenting rhythm, time to ROSC, and induced hypothermia
Variable n HBP
ng/mL
Admission levels
Age, year
<59 79 15.5 (9.1–33.7)
59–68 86 15.7 (9.9–30.2)
>68 80 14.5 (9.9–31.5)
p value 0.967
CA presenting rhythm
Shockable 154 13.1 (8.9–21.5)
Non-shockable 90 21.5 (11.4–46.1)
p value <0.0001
Time to ROSC, min
1–15 83 11.9 (7.9–21.2)
16–24 83 17.4 (9.9–33.2)
25–57 79 18.4 (10.8–41.7)
p value 0.004
48 hour levels
Age, year
<59 75 14.5 (9.7–28.3)
59–68 81 13.5 (9.6–31.1)
>68 66 15.7 (11.7–31.7)
p value 0.619
CA presenting rhythm
Shockable 159 14.1 (9.7–26.1)
Non-shockable 63 19.6 (10.0–59.0)
p value 0.023
Time to ROSC, min
1–15 77 13.2 (8.2–22.6)
16–24 72 15.0 (11.9–28.5)
25–57 73 17.7 (11.5–34.3)
p value 0.038
Induced hypothermia
Yes 175 15.2 (10.5–31.7)
No 47 13.4 (7.7–29.2)
p value 0.086
Data are reported as median and (interquartile range). Age and time to ROSC
are reported as categorical variables divided in their tertiles. p value from
Kruskal-Wallis test
ROSC return of spontaneous circulation
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cantly higher in patients with higher 24 h SOFA scores
(Additional file 2). Moreover, HBP levels were signifi-
cantly higher in patients who developed cardiovascular
failure (Additional file 2) and in those who developed
MODS compared to those who did not (Fig. 1). The areaunder the curve (AUC) of the ROC curve for discrimin-
ation of MODS was 0.70 ± 0.04 (p = 0.0001). A plasma
level of 17.6 ng/mL of HBP had a balanced sensitivity
(0.73) and specificity (0.62) to predict development of
MODS (Fig. 1). The odds ratios for prediction of MODS
are reported in Table 3.
Plasma levels of HBP at ICU admission and 48 h later
were significantly higher in patients who died compared
to those who survived to ICU discharge (Fig. 2). The
odds ratios for prediction of ICU mortality of HBP are
detailed in Table 3. In a multivariable model, including
age, sex, the initial cardiac arrest rhythm (shockable or
non-shockable), time to ROSC, use of adrenaline, and
whether induced hypothermia was applied or not (Table 1),
plasma levels of HBP at ICU admission were independ-
ently associated with ICU death, OR [95 %CI] 1.607
[1.076–2.399] (Table 3). The study had a power of 80 %
(at α = 0.05) to detect an effect size of 1.55 (expressed as
OR), for 1 SD increase in HBP levels, on ICU death.
The AUC of the ROC curve for discrimination of
ICU death was 0.74 ± 0.04 (p < 0.0001, Fig. 2) and a
value of 17.6 ng/mL predicted ICU death with a sen-
sitivity of 0.79 and a specificity of 0.64.
Plasma levels of HBP at ICU admission and at 48 h
later were also significantly higher in patients who had a
poor 12-month neurological outcome compared to those
who had a good recovery (Fig. 2). However, in the multi-
variable model, HBP was not independently associated
with 12-month poor outcome (Table 3). The AUC of the
ROC curve for discrimination of 12-month poor out-
come was 0.65 ± 0.04 (p < 0.0001, Fig. 2). The odds ratios
for prediction of 12-month poor outcome at ICU admis-
sion and 48 h later are detailed in Table 3.
At ICU admission, serum lactate levels were also re-
corded in 72 % of patients. When compared, no difference
between the AUCs of HBP and those of lactate for dis-
crimination of MODS, ICU death, and poor 12-month
outcome (p = 0.36, p = 0.99, and p = 0.97, respectively)
were observed, as described in Additional file 3.
Discussion
The present study suggests that plasma levels of HBP
rise early in patients resuscitated from cardiac arrest.
Indeed, higher plasma levels of HBP at ICU admission
were associated with higher 24 h SOFA score and devel-
opment of MODS and were independently associated
with death in ICU. Plasma levels of HBP were also signifi-
cantly higher in patients with an unfavorable 12-month
neurological outcome compared to those with a favorable
outcome.
HBP is a granule protein mainly derived from neutro-
phils and is released from both secretory vesicles and
azurophilic granules [8, 18]. Secretory vesicles release
HBP rapidly upon cross-linking of β2 integrins on the
Fig. 1 Plasma levels of HBP at ICU admission in patients with or without multiple organ dysfunction syndrome (MODS), and corresponding receiver
operating curve (ROC) and area under the curve (AUC). Data are reported as median and interquartile range; p value from the Kruskal-Wallis test.
HBP heparin-binding protein, SOFA Sequential Organ Failure Assessment
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HBP more slowly. Whole-body ischemia during cardiac
arrest leads to endothelial activation and systemic in-
flammation, and neutrophils are a determinant in the
early step of the inflammatory process [19]. As early as
3 h after resuscitation, blood concentrations of soluble
intercellular adhesion molecule-1, soluble vascular cell
adhesion molecule-1, and P- and E-selectins increase,
suggesting leukocyte and endothelial activation, which
may account for a rapid HBP release [4, 20, 21]. In our
study, the median HBP levels at ICU admission were
already twofold compared to normal values. A potential
role of HBP in the pathogenesis of post-resuscitationTable 3 Univariate and multivariate logistic models for the
prediction of multiple organ dysfunction syndrome (MODS),
ICU death, and 12-month poor outcome
Univariate Multivariate
OR 95 %CI p value OR 95 %CI p value
MODS
HBP, 0 hr 1.339 1.023–1.753 0.034 1.193 0.889–1.601 0.2401
ICU death
HBP, 0 hr 1.843 1.280–2.654 0.001 1.607 1.076–2.399 0.0202
HBP, 48 hr 1.066 0.726–1.565 0.745 0.939 0.595–1.481 0.7863
12-month poor outcome
HBP, 0 hr 1.980 1.170–3.351 0.010 1.454 0.890–2.375 0.1353
HBP, 48 hr 1.337 0.965–1.851 0.081 1.154 0.834–1.596 0.3873
OR, odds ratio per 1 SD increase (SD of HBP is 62.67 at 0 hr and 76.14
at 48 hr)
ICU intensive care unit, CI confidence interval, HBP heparin-binding protein,
CA cardiac arrest, ROSC return of spontaneous circulation
Covariates included in the multivariate models are;
1CA presenting rhythm (shockable vs. not shockable), use of adrenaline, age,
and sex
2CA presenting rhythm (shockable vs. not shockable), use of adrenaline, time
to ROSC (min), induced hypothermia, age, and sex
3CA presenting rhythm (shockable vs. not shockable), use of adrenaline, time
to ROSC (min), induced hypothermia, age, and sexsyndrome cannot be excluded since HBP is known to
induce cytoskeletal rearrangement of endothelial cells
with subsequent breakdown of cell barriers and increases
of the macromolecular efflux [8, 18]. Thus, HBP plays a
central role in endothelial permeability regulation, increas-
ing vascular permeability and leading to edema, hypoper-
fusion, tissue hypoxia, and organ dysfunction [8, 22].
Our study confirms earlier results obtained from 84
patients resuscitated from cardiac arrest, in whom an
early elevation of HBP, i.e., at 6 h and 12 h after resusci-
tation, predicted organ failure and poor 6-month neuro-
logical outcome [10]. In that study, HBP levels at 6 h
yielded an AUC value of 0.68 for discrimination of long-
term poor neurological outcome, which is close to the
moderate AUC of 0.65 observed in our cohort. However,
in contrast to early results, at the multivariate analysis,
high HBP levels were not independently associated with
12-month poor outcome in our population. Our study
was performed on a population more than threefold
greater than Dankiewicz’s study [10] and thereby the
results are likely to be more robust. In addition, in our
population, HBP performance in predicting MODS, ICU
death, and 12-month outcome was similar to that of
serum lactate (Additional file 3), which is one of the
initial laboratory findings widely used to predict mortal-
ity in patients with different critical illnesses, including
cardiac arrest [23, 24]. Thus, HBP admission level is
associated with outcome, but it fails to emerge as a new
prognostic tool superior to other routinely used bio-
markers, i.e., lactate.
HBP levels have been reported to be significantly
higher in ICU patients with severe sepsis or septic shock
compared to patients with a non-septic illness. More
specifically, a plasma HBP concentration of ≥ 15 ng/mL
was associated with development of severe sepsis and
circulatory failure and increased risk of death [11, 12]. In
our study, HBP levels were already > 15 ng/mL at ICU
Fig. 2 Plasma levels of HBP at ICU admission (0 h) and 48 hour later in ICU survivors and non-survivors (on the top) and in patients with favorable
and non-favorable 12-month outcome (on the bottom), with corresponding receiver operating curves (ROC) curve and area under the curves
(AUC). Data are reported as median and interquartile range; p value from Kruskal-Wallis test: *p < 0.05; ***p < 0.0001. HBP heparin-binding protein,
ICU intensive care unit
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who subsequently died in the ICU. Indeed, a level of
HBP > 17.6 ng/mL at ICU admission was associated
with higher risk of developing MODS, and with a 50 %
higher risk of dying in ICU, compared to patients with
lower values.
Earlier studies have also reported that elevated concen-
trations of other inflammatory mediators, i.e., C-reactive
protein or procalcitonin, also correlate with patients’ clin-
ical states and predicted poor outcome after cardiac arrest
[14, 25]. Circulating concentrations of those biomarkers,
however, rise slowly, achieving values predictive of out-
come only after 12 to 24 hours following resuscitation.
In our study, patients exhibiting high HBP already at
ICU admission subsequently developed a more severe
shock and were more likely to die in ICU. Our results re-
semble those of earlier reports in septic patients, indicat-
ing HBP as the best early predictor of vascular failure and
risk of developing circulatory failure and organ dysfunc-
tion, when compared to other laboratory parameters, in-
cluding procalcitonin, interleukin-6 (IL-6), and C-reactive
protein [12, 26]. HBP has been now confirmed as an early
biomarker that may have a clinical role in the prediction
of imminent death after cardiac arrest, similarly to other
early inflammatory biomarkers previously assessed by us
in the same population, i.e., PTX3 and sST2 [15], but with
limited prediction of long-term outcome, in contrast to
others, i.e., IL-6 or kynurenine metabolites [6, 27].Plasma levels of the inflammatory marker HBP were
higher in patients with non-shockable rhythm and with
longer time to ROSC. As previously suggested, because
non-shockable rhythms are usually associated with other
pathological conditions, the high levels of inflammatory
markers may reflect the presence of a general inflamma-
tory status that preceded and/or led to cardiac arrest
[15, 28]. A longer duration of cardiac arrest, including
both no-flow and low-flow times, is known to be associ-
ated with a greater severity of post-cardiac arrest syn-
drome, and plausibly accounted for the higher levels of
HBP [3, 15, 27, 29].
We acknowledge several limitations in the interpret-
ation of our findings. First, this was a biomarker substudy
of the FINNRESUSCI study. Overall, the FINNRESUSCI
population was characterized by a high rate of shockable
cardiac arrests and a favorable outcome [13]. In addition,
some difference between the patients included in this
study and those not included were present (Additional file
1). Indeed, patients with blood samples were somewhat
less severely ill than those without blood samples, as rep-
resented by the significantly greater percentage of shock-
able rhythms and survival to ICU and hospital discharge
and to 1 year with a favorable neurological outcome.
Nevertheless, early HBP elevation was consistently ob-
served after resuscitation in patients who presented poor
early outcome. In addition, all patients with a blood
sample were included in the study and patients had been
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academic hospitals covering the majority of a single coun-
try and thus suggesting generalizability of the results.
Furthermore, in the biomarker analyses, data collection,
outcome evaluation and statistics were performed inde-
pendently. Second, we assayed HBP only at two time
points after resuscitation. However, previous studies both
in sepsis and cardiac arrest have proven the early
prognostic role of this protein and more specifically
within 6–12 h after hospital admission, with subse-
quent decreases [10, 26].
Conclusions
The present study demonstrated in a large population of
out-of-hospital cardiac arrests, that elevated plasma
levels of HBP at ICU admission were associated with
high 24 h SOFA score and were independently associated
with early death in ICU.
Additional files
Additional file 1: Baseline characteristics and clinical factors in all
FINNRESUSCI patients and in patients with blood samples.
Description of data: a table reporting the main clinical characteristics
of the patients included in the overall FINNRESUSCI trial and the
patients included in the present biomarker substudy. (DOCX 14 kb)
Additional file 2: Plasma levels of heparin-binding protein (HBP) at
ICU admission in relationship to the 24-hour SOFA score and 24-hour
cardiovascular SOFA score. Description of data: at ICU admission,
plasma levels of HBP were significantly higher in patients with higher
24 h SOFA scores. Moreover, HBP levels were significantly higher in
patients who developed cardiovascular failure. (DOCX 19 kb)
Additional file 3: Receiver operating characteristic curves of the
discrimination value of plasma HBP at intensive care unit (ICU)
admission and lactate and multiple organ dysfunction syndrome
(MODS), ICU death, and 12-month poor outcome. Description of data:
there was no difference in the areas under the curve (AUCs) of HBP
and lactate for the discrimination of MODS, ICU mortality or 12-month poor
outcome. (DOCX 68 kb)
Abbreviations
AUC, area under the curve; CI, confidence interval; CPC, Cerebral
Performance Category; CPR, cardiopulmonary resuscitation; h, hour;
HBP, heparin-binding protein; ICU, intensive care unit; IL-6, interleukin-6;
IQR, interquartile range; MODS, multiple organ dysfunction syndrome;
OR, odds ratio; ROC, receiver operating curve; ROSC, return of spontaneous
circulation; SOFA, Sequential Organ Failure Assessment
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